(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual revenue growth rate of 93.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Crispr Therapeutics Ag's revenue in 2025 is $38,337,000.On average, 30 Wall Street analysts forecast CRSP's revenue for 2025 to be $1,484,968,231, with the lowest CRSP revenue forecast at $0, and the highest CRSP revenue forecast at $10,668,861,084. On average, 30 Wall Street analysts forecast CRSP's revenue for 2026 to be $12,233,690,910, with the lowest CRSP revenue forecast at $0, and the highest CRSP revenue forecast at $145,523,455,791.
In 2027, CRSP is forecast to generate $27,313,999,780 in revenue, with the lowest revenue forecast at $1,541,004,768 and the highest revenue forecast at $224,241,448,249.